Nuvectra Corporation announced that the U.S. Food and Drug Administration has advised that its review of Company’s pre-market approval application for its Virtis Sacral Neuromodulation system has been extended beyond the expiration of the FDA’s 180-day review period. Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease.